Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 815-461-0
CAS number: -
The pentaeryhritol family consists of 13 substances,
which are all pentaeryhritol esters with linear and branched carboxylic
acids C5-C10. All substances are clear colourless to light yellow
The acute oral and dermal toxicity tests with the
different members of pentaeryhritol family showed the LD50 being high in
all cases. For oral administration the LD50 ranged from > 01940 to >5000
mg/kg/day and for dermal administration the LD50 was higher than 2000
mg/kg body weight. The subacute toxicity test for 28 -days revealed a
NOAEL ranging from 150 to 1000 mg/g/day. Therefore, an extensive
toxicokinetic assessment is considered of limited value. Below, a
summary of the anticipated toxicokinetic behaviour of the pentaeryhritol
family is given.
The water solubility of the pentaeryhritol family is
low (< 01 - < 0.5 mg/l), caused by the presence of the strongly apolar
aliphatic chains. Since in general a compound needs to be dissolved
before it can be taken up from the gastro-intestinal tract, it is
unlikely that the pentaeryhrilol family wil show a high systemic
exposure after oral administration. However, in the presence of food and
bile salts, the solubility will probably be increased and thus the
systemic exposure might be higher. For compounds with a high partition
coeffcient like the pentaeryhritol family also direct uptake via the
lymph is sometimes observed. It is to be expected that the oral
bioavailability, and thus the systemic exposure, of the pentaeryhritol
family will be relatively low.
In the case absorption of the pentaeryhritol family
occurs, extensive cleavage of the ester bonds is anticipated. The
aliphatic chains will probably undergo extensive hydroxylation, followed
by rapid sulfation or glucuronidation. The resulting metabolites will be
extensively excreted via bile and/or urine.
The pentaeryhritol familywill
show a high volume of distribution, because of the high lipophilcity of
the compounds. They will be extensively distributed into peripheral
tissue,especially fatty tissues. Accumulation in fatty tissues is
therefore anticipated. The plasmaprotein binding is expected to
Uptake via inhalation is unlikely because of the
relatively large particles.
Since it is generally accepted that substances with
log Po/w ranging from 0.1 to 6 penetrate the skin easily, it is to be
expected that the pentaeryhritol family in general hardly penetrates theskin.
Based on the expected kinetic behaviour in the body,
as described above, the members of the pentaeryhrilol family will hardly
be absorbed after oral administration, mainly because of their low
solubility. If absorption occurs, these compounds will be extensively
metabolised in the liver or plasma and rapidly excreted via bile and/or
urine. Therefore, accumulation in the body during prolonged exposure
will be very low, although some retention in fatty tissues may occur.
Since the chemical structures of the members of the
pentaeryhritol family are strongly comparable, and the physical,
chemical, and toxicological data are in a narrow range, it is to be
expected that the toxicokinetic behaviour of the different compounds
will follow the same pattern.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again